Read + Share
Mato AR, Ghosh N, Schuster SJ, Lamanna N, et al. Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who
are intolerant to BTK or PI3Kdelta inhibitor therapy. Blood 2021;137:2817-2826.
PMID: 33259589
|
 |
|
Mato AR, Ghosh N, Schuster SJ, Lamanna N, et al. Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who
are intolerant to BTK or PI3Kdelta inhibitor therapy. Blood 2021;137:2817-2826.
PMID: 33259589
|
|
|
|